Cytokines in diabetic nephropathy

Advances in Clinical Chemistry

Volumn 56, Issue , 2012, Pages 55-74

  Wu, Chia Chao ^a,b   Sytwu, Huey Kang ^b   Lin, Yuh Feng ^a,c,d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Shuang Ho Hospital   (Taiwan)

Author keywords

Albuminuria; Cytokines; Hemodynamic factors; Macrophage; TNF

Indexed keywords

EID: 84855337303     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394317-0.00014-5     Document Type: Chapter

References (134)

1. Caramori M.L., Mauer M. Diabetes and nephropathy. Curr. Opin. Nephrol. Hypertens. 2003, 12:273-282.
2. Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2002, 346:1145-1151.
3. Ritz E., Rychlik I., Locatelli F., Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 1999, 34:795-808.
4. Wolf G., Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J. Am. Soc. Nephrol. 2003, 14:1396-1405.
5. Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001, 44:1957-1972.
6. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
7. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur. J. Clin. Invest. 2004, 34:785-796.
8. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
9. Frohlich M., Imhof A., Berg G., Hutchinson W.L., Pepys M.B., Boeing H., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835-1839.
10. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
11. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008, 19:433-442.
12. Rivero A., Mora C., Muros M., Garcia J., Herrera H., Navarro-Gonzalez J.F. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin. Sci. (Lond.) 2009, 116:479-492.
13. Balkwill F.R., Burke F. The cytokine network. Immunol. Today 1989, 10:299-304.
14. Mora C., Navarro J.F. Inflammation and diabetic nephropathy. Curr. Diab. Rep. 2006, 6:463-468.
15. Navarro J.F., Mora C. Role of inflammation in diabetic complications. Nephrol. Dial. Transplant. 2005, 20:2601-2604.
16. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
17. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 1996, 17:138-146.
18. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 2009, 361:888-898.
19. Ha H., Yu M.R., Choi Y.J., Kitamura M., Lee H.B. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 2002, 13:894-902.
20. Chen J.S., Lee H.S., Jin J.S., Chen A., Lin S.H., Ka S.M., et al. Attenuation of mouse mesangial cell contractility by high glucose and mannitol: involvement of protein kinase C and focal adhesion kinase. J. Biomed. Sci. 2004, 11:142-151.
21. Bohlender J.M., Franke S., Stein G., Wolf G. Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 2005, 289:F645-F659.
22. Goh S.Y., Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1143-1152.
23. Lee F.T., Cao Z., Long D.M., Panagiotopoulos S., Jerums G., Cooper M.E., et al. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 2004, 15:2139-2151.
24. Mezzano S., Droguett A., Burgos M.E., Ardiles L.G., Flores C.A., Aros C.A., et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int. 2003, 64(86s):S64-S70.
25. Kanetsuna Y., Takahashi K., Nagata M., Gannon M.A., Breyer M.D., Harris R.C., et al. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am. J. Pathol. 2007, 170:1473-1484.
26. Fornoni A., Ijaz A., Tejada T., Lenz O. Role of inflammation in diabetic nephropathy. Curr. Diabetes Rev. 2008, 4:10-17.
27. Navarro J.F., Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 2006, 17:441-450.
28. Wolf G. Growth factors and the development of diabetic nephropathy. Curr. Diab. Rep. 2003, 3:485-490.
29. Dronavalli S., Duka I., Bakris G.L. The pathogenesis of diabetic nephropathy. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:444-452.
30. Jevnikar A.M., Brennan D.C., Singer G.G., Heng J.E., Maslinski W., Wuthrich R.P., et al. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. Kidney Int. 1991, 40:203-211.
31. Sugimoto H., Shikata K., Wada J., Horiuchi S., Makino H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999, 42:878-886.
32. Dong X., Swaminathan S., Bachman L.A., Croatt A.J., Nath K.A., Griffin M.D. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int. 2007, 71:619-628.
33. Zhang B., Ramesh G., Norbury C.C., Reeves W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 2007, 72:37-44.
34. Navarro J.F., Mora C., Maca M., Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am. J. Kidney Dis. 2003, 42:53-61.
35. Navarro J.F., Milena F.J., Mora C., Leon C., Claverie F., Flores C., et al. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. 2005, 68(99s):S98-S102.
36. Navarro J.F., Milena F.J., Mora C., Leon C., Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am. J. Nephrol. 2006, 26:562-570.
37. Bertani T., Abbate M., Zoja C., Corna D., Perico N., Ghezzi P., et al. Tumor necrosis factor induces glomerular damage in the rabbit. Am. J. Pathol. 1989, 134:419-430.
38. Baud L., Ardaillou R. Tumor necrosis factor in renal injury. Miner. Electrolyte Metab. 1995, 21:336-341.
39. Ruiz-Ortega M., Lorenzo O., Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int. 2000, 57:2285-2298.
40. Ortiz A., Bustos C., Alonso J., Alcazar R., Lopez-Armada M.J., Plaza J.J., et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv. Nephrol. Necker Hosp. 1995, 24:53-77.
41. Laster S.M., Wood J.G., Gooding L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J. Immunol. 1988, 141:2629-2634.
42. Boyle J.J., Weissberg P.L., Bennett M.R. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1553-1558.
43. Koike N., Takamura T., Kaneko S. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor. Life Sci. 2007, 80:1721-1728.
44. Ohmori M., Harada K., Kitoh Y., Nagasaka S., Saito T., Fujimura A. The functions of circulatory polymorphonuclear leukocytes in diabetic patients with and without diabetic triopathy. Life Sci. 2000, 66:1861-1870.
45. McCarthy E.T., Sharma R., Sharma M., Li J.Z., Ge X.L., Dileepan K.N., et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J. Am. Soc. Nephrol. 1998, 9:433-438.
46. DiPetrillo K., Coutermarsh B., Gesek F.A. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am. J. Physiol. Renal Physiol. 2003, 284:F113-F121.
47. Moriwaki Y., Yamamoto T., Shibutani Y., Aoki E., Tsutsumi Z., Takahashi S., et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003, 52:605-608.
48. Navarro J.F., Mora C., Rivero A., Gallego E., Chahin J., Macia M., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 1999, 33:458-463.
49. Navarro J.F., Mora C., Muros M., Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol. Dial. Transplant. 2006, 21:3428-3434.
50. Kalantarinia K., Awad A.S., Siragy H.M. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003, 64:1208-1213.
51. Sassy-Prigent C., Heudes D., Mandet C., Belair M.F., Michel O., Perdereau B., et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000, 49:466-475.
52. Royall J.A., Berkow R.L., Beckman J.S., Cunningham M.K., Matalon S., Freeman B.A. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol. 1989, 257:L399-L410.
53. Pfeilschifter J., Pignat W., Vosbeck K., Marki F. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem. Biophys. Res. Commun. 1989, 159:385-394.
54. Brady H.R. Leukocyte adhesion molecules and kidney diseases. Kidney Int. 1994, 45:1285-1300.
55. Park C.W., Kim J.H., Lee J.H., Kim Y.S., Ahn H.J., Shin Y.S., et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 2000, 43:1544-1553.
56. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol. Today 1990, 11:443-449.
57. Sekizuka K., Tomino Y., Sei C., Kurusu A., Tashiro K., Yamaguchi Y., et al. Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 1994, 68:284-285.
58. Suzuki D., Miyazaki M., Naka R., Koji T., Yagame M., Jinde K., et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995, 44:1233-1238.
59. Nosadini R., Velussi M., Brocco E., Bruseghin M., Abaterusso C., Saller A., et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000, 49:476-484.
60. Thomson S.C., Deng A., Bao D., Satriano J., Blantz R.C., Vallon V. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J. Clin. Invest. 2001, 107:217-224.
61. Dalla V.M., Mussap M., Gallina P., Bruseghin M., Cernigoi A.M., Saller A., et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 2005, 16(Suppl. 1):S78-S82.
62. Ruef C., Budde K., Lacy J., Northemann W., Baumann M., Sterzel R.B., et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int. 1990, 38:249-257.
63. Coleman D.L., Ruef C. Interleukin-6: an autocrine regulator of mesangial cell growth. Kidney Int. 1992, 41:604-606.
64. Dai S.M., Matsuno H., Nakamura H., Nishioka K., Yudoh K. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum. 2004, 50:432-443.
65. Melnikov V.Y., Ecder T., Fantuzzi G., Siegmund B., Lucia M.S., Dinarello C.A., et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J. Clin. Invest. 2001, 107:1145-1152.
66. Melnikov V.Y., Faubel S., Siegmund B., Lucia M.S., Ljubanovic D., Edelstein C.L. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J. Clin. Invest. 2002, 110:1083-1091.
67. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88-91.
68. Schwarz M., Wahl M., Resch K., Radeke H.H. IFNgamma induces functional chemokine receptor expression in human mesangial cells. Clin. Exp. Immunol. 2002, 128:285-294.
69. Marino E., Cardier J.E. Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD95). Cytokine 2003, 22:142-148.
70. Stuyt R.J., Netea M.G., Geijtenbeek T.B., Kullberg B.J., Dinarello C.A., van der Meer J.W. Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology 2003, 110:329-334.
71. Nakamura A., Shikata K., Hiramatsu M., Nakatou T., Kitamura T., Wada J., et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005, 28:2890-2895.
72. Araki S., Haneda M., Koya D., Sugimoto T., Isshiki K., Chin-Kanasaki M., et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia 2007, 50:867-873.
73. Wu C.C., Chen J.S., Lu K.C., Chen C.C., Lin S.H., Chu P., et al. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin. Chim. Acta 2010, 411:700-704.
74. Lalani I., Bhol K., Ahmed A.R. Interleukin-10: biology, role in inflammation and autoimmunity. Ann. Allergy Asthma Immunol. 1997, 79:469-483.
75. van Exel E., Gussekloo J., de Craen A.J., Frolich M., Bootsma-Van Der W.A., Westendorp R.G. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002, 51:1088-1092.
76. Mysliwska J., Zorena K., Semetkowska-Jurkiewicz E., Rachon D., Suchanek H., Mysliwski A. High levels of circulating interleukin-10 in diabetic nephropathy patients. Eur. Cytokine Netw. 2005, 16:117-122.
77. Wong C.K., Ho A.W., Tong P.C., Yeung C.Y., Kong A.P., Lun S.W., et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin. Exp. Immunol. 2007, 149:123-131.
78. Zamauskaite A., Yaqoob M.M., Madrigal J.A., Cohen S.B. The frequency of Th2 type cells increases with time on peritoneal dialysis in patients with diabetic nephropathy. Eur. Cytokine Netw. 1999, 10:219-226.
79. Bending D., De La P.H., Veldhoen M., Phillips J.M., Uyttenhove C., Stockinger B., et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 2009, 119:565-572.
80. Bradshaw E.M., Raddassi K., Elyaman W., Orban T., Gottlieb P.A., Kent S.C., et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J. Immunol. 2009, 183:4432-4439.
81. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., et al. IL-17 immunity in human type 1 diabetes. J. Immunol. 2010, 185:1959-1967.
82. Jagannathan-Bogdan M., McDonnell M.E., Shin H., Rehman Q., Hasturk H., Apovian C.M., et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol. 2010, 186:1162-1172.
83. Arababadi M.K., Nosratabadi R., Hassanshahi G., Yaghini N., Pooladvand V., Shamsizadeh A., et al. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases?. Diabetes Res. Clin. Pract. 2010, 87:33-37.
84. Lawrence D.A. Transforming growth factor-beta: an overview. Kidney Int. Suppl. 1995, 49:S19-S23.
85. Hoffman B.B., Sharma K., Zhu Y., Ziyadeh F.N. Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int. 1998, 54:1107-1116.
86. McLennan S.V., Death A.K., Fisher E.J., Williams P.F., Yue D.K., Turtle J.R. The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. Cell. Mol. Biol. (Noisy-le-Grand) 1999, 45:123-135.
87. McGowan T.A., Zhu Y., Sharma K. Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr. Diab. Rep. 2004, 4:447-454.
88. Zhu Y., Usui H.K., Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin. Nephrol. 2007, 27:153-160.
89. Chiarelli F., Gaspari S., Marcovecchio M.L. Role of growth factors in diabetic kidney disease. Horm. Metab. Res. 2009, 41:585-593.
90. Sanchez A.P., Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev. Mol. Med. 2009, 11:e13.
91. van den Heuvel M., Batenburg W.W., Danser A.H. Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis?. Mol. Cell. Endocrinol. 2009, 302:213-218.
92. Rich S.S. Genetics of diabetes and its complications. J. Am. Soc. Nephrol. 2006, 17:353-360.
93. Pezzolesi M.G., Poznik G.D., Mychaleckyj J.C., Paterson A.D., Barati M.T., Klein J.B., et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 2009, 58:1403-1410.
94. Ahluwalia T.S., Khullar M., Ahuja M., Kohli H.S., Bhansali A., Mohan V., et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 2009, 4:e5168.
95. Seaquist E.R., Goetz F.C., Rich S., Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N. Engl. J. Med. 1989, 320:1161-1165.
96. Lee S.H., Lee T.W., Ihm C.G., Kim M.J., Woo J.T., Chung J.H. Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation. Nephrology (Carlton) 2005, 10(Suppl.):S32-S36.
97. Lindholm E., Bakhtadze E., Cilio C., Agardh E., Groop L., Agardh C.D. Association between LTA, TNF and AGER polymorphisms and late diabetic complications. PLoS One 2008, 3:e2546.
98. Blakemore A.I., Cox A., Gonzalez A.M., Maskil J.K., Hughes M.E., Wilson R.M., et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum. Genet. 1996, 97:369-374.
99. Lee S.H., Ihm C.G., Sohn S.D., Lee T.W., Kim M.J., Koh G., et al. Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. Am. J. Nephrol. 2004, 24:410-414.
100. Loughrey B.V., Maxwell A.P., Fogarty D.G., Middleton D., Harron J.C., Patterson C.C., et al. An interleukin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. Cytokine 1998, 10:984-988.
101. Mysliwska J., Zorena K., Mysliwiec M., Malinowska E., Raczynska K., Balcerska A. The-174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr. Res. 2009, 66:341-345.
102. Kitamura A., Hasegawa G., Obayashi H., Kamiuchi K., Ishii M., Yano M., et al. Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet. Med. 2002, 19:1000-1005.
103. Wang H., Zhang Z., Chu W., Hale T., Cooper J.J., Elbein S.C. Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J. Clin. Endocrinol. Metab. 2005, 90:1123-1129.
104. Kim L.H., Lee H.S., Kim Y.J., Jung J.H., Kim J.Y., Park B.L., et al. Identification of novel SNPs in the interleukin 6 receptor gene (IL6R). Hum. Mutat. 2003, 21:450-451.
105. Szeto C.C., Chow K.M., Poon P.Y., Kwan B.C., Li P.K. Association of interleukin-18 promoter polymorphism and atherosclerotic diseases in Chinese patients with diabetic nephropathy. Nephrology (Carlton) 2009, 14:606-612.
106. Bugawan T.L., Mirel D.B., Valdes A.M., Panelo A., Pozzilli P., Erlich H.A. Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos. Am. J. Hum. Genet. 2003, 72:1505-1514.
107. Masutani K., Miyake K., Nakashima H., Hirano T., Kubo M., Hirakawa M., et al. Impact of interferon-gamma and interleukin-4 gene polymorphisms on development and progression of IgA nephropathy in Japanese patients. Am. J. Kidney Dis. 2003, 41:371-379.
108. Miyake K., Nakashima H., Akahoshi M., Inoue Y., Nagano S., Tanaka Y., et al. Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis. Rheumatology (Oxford) 2002, 41:518-524.
109. Mittal R.D., Manchanda P.K. Association of interleukin (IL)-4 intron-3 and IL-6-174 G/C gene polymorphism with susceptibility to end-stage renal disease. Immunogenetics 2007, 59:159-165.
110. Mtiraoui N., Ezzidi I., Kacem M., Ben Hadj M.M., Chaieb M., Haj Jilani A.B., et al. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes Metab. Res. Rev. 2009, 25:57-63.
111. Ezzidi I., Mtiraoui N., Kacem M., Mallat S.G., Mohamed M.B., Chaieb M., et al. Interleukin-10-592C/A,-819C/T and-1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. Clin. Endocrinol. (Oxf) 2009, 70:401-407.
112. Prasad P., Tiwari A.K., Kumar K.M., Ammini A.C., Gupta A., Gupta R., et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med. Genet. 2007, 8:20.
113. Wong T.Y., Poon P., Chow K.M., Szeto C.C., Cheung M.K., Li P.K. Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int. 2003, 63:1831-1835.
114. Akai Y., Sato H., Ozaki H., Iwano M., Dohi Y., Kanauchi M. Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am. J. Kidney Dis. 2001, 38:S182-S185.
115. Pociot F., Hansen P.M., Karlsen A.E., Langdahl B.L., Johannesen J., Nerup J. TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. J. Am. Soc. Nephrol. 1998, 9:2302-2307.
116. Turgut F., Bolton W.K. Potential new therapeutic agents for diabetic kidney disease. Am. J. Kidney Dis. 2010, 55:928-940.
117. Dagenais N.J., Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005, 25:1213-1229.
118. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 2006, 17:1362-1372.
119. Utimura R., Fujihara C.K., Mattar A.L., Malheiros D.M., Noronha I.L., Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 2003, 63:209-216.
120. Moriwaki Y., Inokuchi T., Yamamoto A., Ka T., Tsutsumi Z., Takahashi S., et al. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol. 2007, 44:215-218.
121. Benigni A., Zoja C., Corna D., Zatelli C., Conti S., Campana M., et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 2003, 14:1816-1824.
122. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 2000, 97:8015-8020.
123. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530.
124. Chen S., Iglesias-de la Cruz M.C., Jim B., Hong S.W., Isono M., Ziyadeh F.N. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem. Biophys. Res. Commun. 2003, 300:16-22.
125. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
126. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
127. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Ehses J.A. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009, 24:325-331.
128. McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am. J. Kidney Dis. 2008, 52:454-463.
129. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 1990, 172:391-394.
130. Tissi L., Puliti M., Barluzzi R., Orefici G., von Hunolstein C., Bistoni F. Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis. Infect. Immun. 1999, 67:4545-4550.
131. Doherty G.M., Jensen J.C., Alexander H.R., Buresh C.M., Norton J.A. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991, 110:192-198.
132. DiPetrillo K., Gesek F.A. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am. J. Nephrol. 2004, 24:352-359.
133. Navarro J.F., Mora C., Muros M., Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J. Am. Soc. Nephrol. 2005, 16:2119-2126.
134. Ortiz-Munoz G., Lopez-Parra V., Lopez-Franco O., Fernandez-Vizarra P., Mallavia B., Flores C., et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:763-772.